NRP1 and neoplasm: Another added advantage of our liposomal formulation is that we have tagged a proprietary tumor-targeting peptide (TTP) to the surface of the liposomes to enhance the tumor-specific delivery of the drugs and reduce any toxicity arising from the treatment of Everolimus as well as systemic inhibition of NRP1.